BioSpace News Archive

Pressure BioSciences, Inc. announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

Brenus Pharma, French biotech developing its proprietary discovery platform: “Stimulated-Tumor-Cell”, has presented the study design of “BreAK-CRC” First-in-human of STC-1010, Brenus’ lead candidate, during ASCO annual meeting - Trials in Progress poster session, in Chicago.

ABIONYX Pharma announced that the company has completed a pre-IND meeting with the US Food and Drug Administration and has received feedback to support an IND filing for its candidate drug.

Nexalin Technology, Inc. announced that its second generation, 15 milliamp neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices.

Pliant Therapeutics, Inc., a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced the appointment of Steve Krognes to its Board of Directors.

IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, presents updated data from its Phase 1 trial of INB-100 at the European Hematology Association 2024 Hybrid Congress.

Specialty diagnostics company Precipio, Inc., announced that the company’s 2024 Annual Meeting of Shareholders was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Rezolute, Inc., a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, announced that it is commencing an underwritten public offering of shares of its common stock.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystrophy, that demonstrated robust and durable DUX4 suppression and functional benefit.